FOXP3 and cancer: Recently, we found that combinations with CCL5/CCR5 antagonist and the anti-PD-L1 antibody inhibited tumor growth and improved overall survival in mice models of PDAC.5 Here, we first determined that cancer-FOXP3 mediated immune escape by recruiting regulatory T cells via upregulation of CCL5.